Drugs / NT219
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06919666 | Jun 2025 → Feb 2030 expected | head and neck squamous cell carcinoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04474470 | Sep 2020 → May 2024 | colorectal adenocarcinoma, head and neck squamous cell carcinoma, metastatic neoplasm | TyrNovo Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06919666 ↗ |
| Modality | Small molecule | — CHEMBL3679680 ↗ |
| Route | Intravenous | “Patients will be treated with NT219 75 mg/kg IV once weekly plus pembrolizumab 200 mg once every three weeks.” NCT06919666 ↗ |